NASDAQ · IPSC
Century Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IPSC: Nov 12, 2026
Century Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.12 | $-0.12 | $-0.12 | 2 |
| Dec 2026 | $-0.13 | $-0.12 | $-0.13 | 2 |
| Mar 2027 | $-0.13 | $-0.12 | $-0.13 | 2 |
| Jun 2027 | $-0.13 | $-0.12 | $-0.13 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · The Motley Fool- RTTNews · Oct 2, 9:15 AM EDTCentury Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data(RTTNews) – Century Therapeutics, Inc. (IPSC), a biotechnology company, presented new nonclinical data for CNTY-813, its investigational iPSC-derived islet replacement therapy for type 1 diabetes. The data were presented in an oral presentation at the 62nd Annual Meeting of the E
- RTTNews · Sep 10, 3:13 AM EDTCentury Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing(RTTNews) – Century Therapeutics, Inc. (IPSC), a biotechnology company, announced the appointment of Joseph Truitt to its Board of Directors.
- RTTNews · Aug 12, 2:02 PM EDTCentury Advances CNTY-813; IND Submission On Track For Q4 2026(RTTNews) – Century Therapeutics, Inc. (IPSC), a biotechnology company developing iPSC-derived cell therapies for autoimmune diseases and cancer, reported second-quarter 2026 financial results and business updates, highlighting regulatory progress for CNTY-813, a potential functi
- Fintel · May 27, 5:14 PM EDTMizuho Initiates Coverage of Century Therapeutics (IPSC) with Outperform RecommendationFintel reports that on May 27, 2026, Mizuho initiated coverage of Century Therapeutics (NasdaqCM:IPSC) with a Outperform recommendation. Analyst Price Forecast Suggests 106.82% Upside
- Fintel · Feb 3, 6:59 PM ESTCentury Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20The average one-year price target for Century Therapeutics (NasdaqCM:IPSC) has been revised to $4.20 / share. This is an increase of 10.75% from the prior estimate of $3.79 dated January 11, 2026. The price target is an average of many targets provided by anal
- RTTNews · Jan 27, 5:34 AM ESTAre Biotech And Pharma Stocks Poised To Keep Climbing After Hitting 52-Week Highs?(RTTNews) – Biotech and life sciences stocks have continued their strong momentum into 2026, with several profiled companies hitting fresh 52-week and all-time highs. Strategic financings, acquisitions, breakthrough designations, and robust revenue growth have fueled investor con
- Zacks · Jan 22, 12:00 PM ESTCentury Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should KnowCentury Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Zacks · Jan 7, 11:45 AM ESTFDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy DrugAlkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
- Zacks · Jan 7, 8:55 AM ESTFast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a BargainIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- Zacks · Dec 9, 8:55 AM ESTWhy Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value InvestorsIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- The Motley Fool · Aug 14, 6:03 PM EDTCentury Reports Flat Loss in Fiscal Q2Century Therapeutics reported a GAAP EPS loss of $0.3761 and no revenue for Q2 2025, matching analyst estimates.
- Zacks · Jul 21, 12:00 PM EDTAll You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong BuyCentury Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Century Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.